Dermapharm Holding SE
DMPHF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.36B
Close$
$57.19
19.9% upside
Current Fair Value
19.9% upsideUndervalued by 19.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.36 Billion |
|---|---|
| Enterprise Value | $3.33 Billion |
| Annual dividend | $1.01 |
| Dividend yield | 2.29% |
| Earnings per Share | $2.46 |
| Beta | 0.85 |
| Outstanding Shares | 49,540,810 |
Return
| Return on Equity | 27.38% |
|---|---|
| Return on Assets | 6.55% |
| Return on Invested Capital | 14.80% |
Valuation & Multiples
| P/E Ratio | 13.86 |
|---|---|
| PEG | 126.2 |
| Price to Sales | 2.07 |
| Price to Book Ratio | 4.77 |
| Enterprise Value to Revenue | 2.82 |
| Enterprise Value to EBIT | 12.56 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0.35 |
| Debt to Equity | 2.18 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
$0.54
Consensus analyst estimateRevenue Estimate
$325.72 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$345.52 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Dermapharm Holding SE
3,619 employees
CEO: Hans-Georg Feldmeier
Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Brande...